BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, Blakkisrud J, Løndalen A, O'Rourke N, Beasley M, Jurczak W, Fagerli UM, Kaščák M, Bayne M, Obr A, Dahle J, Rojkjaer L, Pascal V, Holte H. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv 2020;4:4091-101. [PMID: 32877524 DOI: 10.1182/bloodadvances.2020002583] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Blakkisrud J, Løndalen A, Dahle J, Martinsen AC, Kolstad A, Stokke C. Myelosuppression in patients treated with 177Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable. Acta Oncol 2021;60:1481-8. [PMID: 34425735 DOI: 10.1080/0284186X.2021.1959635] [Reference Citation Analysis]
2 Duan H, Iagaru A, Aparici CM. Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging. Nanotheranostics 2022;6:103-17. [PMID: 34976584 DOI: 10.7150/ntno.64141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Parakh S, Lee ST, Gan HK, Scott AM. Radiolabeled Antibodies for Cancer Imaging and Therapy. Cancers 2022;14:1454. [DOI: 10.3390/cancers14061454] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Giesen D, Hooge MNL, Nijland M, Heyerdahl H, Dahle J, de Vries EGE, Pool M. 89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma. Sci Rep 2022;12:6286. [PMID: 35428777 DOI: 10.1038/s41598-022-10139-6] [Reference Citation Analysis]
5 Lassmann M, Eberlein U, Gear J, Konijnenberg M, Kunikowska J. Dosimetry for Radiopharmaceutical Therapy: The European Perspective. J Nucl Med 2021;62:73S-9S. [PMID: 34857624 DOI: 10.2967/jnumed.121.262754] [Reference Citation Analysis]
6 Koziorowski J, Ballinger J. Theragnostic radionuclides: a clinical perspective. Q J Nucl Med Mol Imaging 2021;65:306-14. [PMID: 34881851 DOI: 10.23736/S1824-4785.21.03424-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Qualls D, Salles G. Prospects in the management of patients with follicular lymphoma beyond first-line therapy. Haematologica 2022;107:19-34. [PMID: 34985231 DOI: 10.3324/haematol.2021.278717] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Løndalen A, Blakkisrud J, Revheim ME, Madsbu UE, Dahle J, Kolstad A, Stokke C. FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2021;48:1902-14. [PMID: 33196921 DOI: 10.1007/s00259-020-05098-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Løndalen A, Blakkisrud J, Revheim ME, Dahle J, Kolstad A, Stokke C. FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target? Mol Imaging Biol 2022. [PMID: 35486292 DOI: 10.1007/s11307-022-01731-3] [Reference Citation Analysis]